{"id":401589,"date":"2020-12-17T06:48:20","date_gmt":"2020-12-17T11:48:20","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=401589"},"modified":"2020-12-17T06:48:20","modified_gmt":"2020-12-17T11:48:20","slug":"annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3\/","title":{"rendered":"Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">BERWYN, Pa., Dec.  17, 2020  (GLOBE NEWSWIRE) &#8212; Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer\u2019s disease (AD), Parkinson\u2019s disease (PD) and other neurodegenerative diseases, today announced an interview with its CEO, Maria Maccecchini, Ph.D., will air on <em>The RedChip Money Report <\/em>television program. <em>The RedChip Money Report<\/em> airs in 100 million homes on Sundays at 6 p.m. local time in every country in Europe on Bloomberg International.<\/p>\n<p align=\"justify\">In the exclusive interview, Dr. Maccecchini discusses the Company\u2019s unique approach to AD and other neurodegenerative diseases, current clinical trials underway, and upcoming milestones.<\/p>\n<p align=\"justify\">To view the interview segment, please visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RB1dKmLZJNFlepD2e_H45Pq4hfllR9DZIoMaIhHvFU0kZXNLtgw5nylOk6-_SsENzhhdLA8erswYUMB_KBy6IfI6IcdFn14L5OUiUdBhycE=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/youtu.be\/GVakTzykHYg<\/a><\/p>\n<p align=\"justify\">\u201cThe RedChip Money Report&#8221; delivers insightful commentary on small cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.<\/p>\n<p align=\"justify\">\n        <strong>About Annovis Bio<\/strong>\n      <\/p>\n<p align=\"justify\">Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer\u2019s disease (AD), Parkinson\u2019s disease (PD) and Alzheimer\u2019s in Down Syndrome (AD-DS). We believe that we are the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. We have an ongoing Phase 2a study in AD patients and have commenced a second Phase 2a study in AD and PD patients. For more information on Annovis, please visit the company\u2019s website:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XVOb_s5tSpswkIb15-x37uAfz6xBV0UuZHLMBCY5T9oW8qUJLyz1omK9ZXlp4WNnlDJcqeOAJu2GggyaCWjbb99uxdQeIs_cd8MX2ITkNoo=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.annovisbio.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">Statements in this press release contain \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cexpect,\u201d \u201cbelieve,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201coutlook,\u201d \u201cforecast\u201d or other similar words, and include, without limitation, statements regarding the timing, effectiveness and anticipated results of ANVS401 clinical trials. Forward-looking statements are based on Annovis Bio, Inc.\u2019s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including that clinical trials may be delayed. These and other risks and uncertainties are described more fully in the section titled \u201cRisk Factors\u201d in the Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.<\/p>\n<p>Investor Relations:<\/p>\n<p>Dave Gentry, CEO<br \/>RedChip Companies Inc.<br \/>407-491-4498<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yED-quznaVyQBATItSLzy2REkXm1ByoJIXHIA-EIWmPbIxIrEbnfoQSl-zVCaY3N3lAULat_MIVhXb2nc-_mIA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Dave@redchip.com<\/a><\/p>\n<p>SOURCE: Annovis Bio, Inc.<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNDAxOSMzODg2NTAyIzIxOTQ4NTA=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/48ece4b5-8568-452d-8168-c14d6750efa8\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BERWYN, Pa., Dec. 17, 2020 (GLOBE NEWSWIRE) &#8212; Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer\u2019s disease (AD), Parkinson\u2019s disease (PD) and other neurodegenerative diseases, today announced an interview with its CEO, Maria Maccecchini, Ph.D., will air on The RedChip Money Report television program. The RedChip Money Report airs in 100 million homes on Sundays at 6 p.m. local time in every country in Europe on Bloomberg International. In the exclusive interview, Dr. Maccecchini discusses the Company\u2019s unique approach to AD and other neurodegenerative diseases, current clinical trials underway, and upcoming milestones. To view the interview segment, please visit: https:\/\/youtu.be\/GVakTzykHYg \u201cThe RedChip Money Report&#8221; delivers insightful commentary on small cap investing, interviews with Wall Street &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-401589","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BERWYN, Pa., Dec. 17, 2020 (GLOBE NEWSWIRE) &#8212; Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer\u2019s disease (AD), Parkinson\u2019s disease (PD) and other neurodegenerative diseases, today announced an interview with its CEO, Maria Maccecchini, Ph.D., will air on The RedChip Money Report television program. The RedChip Money Report airs in 100 million homes on Sundays at 6 p.m. local time in every country in Europe on Bloomberg International. In the exclusive interview, Dr. Maccecchini discusses the Company\u2019s unique approach to AD and other neurodegenerative diseases, current clinical trials underway, and upcoming milestones. To view the interview segment, please visit: https:\/\/youtu.be\/GVakTzykHYg \u201cThe RedChip Money Report&#8221; delivers insightful commentary on small cap investing, interviews with Wall Street &hellip; Continue reading &quot;Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-17T11:48:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNDAxOSMzODg2NTAyIzIxOTQ4NTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report\",\"datePublished\":\"2020-12-17T11:48:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3\\\/\"},\"wordCount\":494,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExNDAxOSMzODg2NTAyIzIxOTQ4NTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3\\\/\",\"name\":\"Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExNDAxOSMzODg2NTAyIzIxOTQ4NTA=\",\"datePublished\":\"2020-12-17T11:48:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExNDAxOSMzODg2NTAyIzIxOTQ4NTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExNDAxOSMzODg2NTAyIzIxOTQ4NTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3\/","og_locale":"en_US","og_type":"article","og_title":"Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report - Market Newsdesk","og_description":"BERWYN, Pa., Dec. 17, 2020 (GLOBE NEWSWIRE) &#8212; Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer\u2019s disease (AD), Parkinson\u2019s disease (PD) and other neurodegenerative diseases, today announced an interview with its CEO, Maria Maccecchini, Ph.D., will air on The RedChip Money Report television program. The RedChip Money Report airs in 100 million homes on Sundays at 6 p.m. local time in every country in Europe on Bloomberg International. In the exclusive interview, Dr. Maccecchini discusses the Company\u2019s unique approach to AD and other neurodegenerative diseases, current clinical trials underway, and upcoming milestones. To view the interview segment, please visit: https:\/\/youtu.be\/GVakTzykHYg \u201cThe RedChip Money Report&#8221; delivers insightful commentary on small cap investing, interviews with Wall Street &hellip; Continue reading \"Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-17T11:48:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNDAxOSMzODg2NTAyIzIxOTQ4NTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report","datePublished":"2020-12-17T11:48:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3\/"},"wordCount":494,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNDAxOSMzODg2NTAyIzIxOTQ4NTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3\/","name":"Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNDAxOSMzODg2NTAyIzIxOTQ4NTA=","datePublished":"2020-12-17T11:48:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNDAxOSMzODg2NTAyIzIxOTQ4NTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNDAxOSMzODg2NTAyIzIxOTQ4NTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/annovis-bio-interview-to-air-on-bloomberg-international-on-the-redchip-money-report-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/401589","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=401589"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/401589\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=401589"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=401589"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=401589"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}